Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin.
about
Androgen biosynthesis in castration-resistant prostate cancerStructure-based inhibitor design for an enzyme that binds different steroids: a potent inhibitor for human type 5 17beta-hydroxysteroid dehydrogenaseCrystal Structures of Three Classes of Non-Steroidal Anti-Inflammatory Drugs in Complex with Aldo-Keto Reductase 1C3Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate CancerStructure of AKR1C3 with 3-phenoxybenzoic acid boundIdentification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug designStructures of complexes of type 5 17β-hydroxysteroid dehydrogenase with structurally diverse inhibitors: insights into the conformational changes upon inhibitor bindingCombined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemiaAnthranilic acid analogs as diamagnetic CEST MRI contrast agents that feature an intramolecular-bond shifted hydrogen.Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cellsLack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancersMetabolism of the synthetic progestogen norethynodrel by human ketosteroid reductases of the aldo-keto reductase superfamilySelective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment libraryInhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.Substrate specificity and inhibitor analyses of human steroid 5β-reductase (AKR1D1)Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.Crystallization and preliminary X-ray diffraction analysis of mouse prostaglandin F2α synthase, AKR1B3.Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.Biological role of aldo-keto reductases in retinoic Acid biosynthesis and signaling.Pentafluorosulfanyl-containing flufenamic acid analogs: Syntheses, properties and biological activitiesNetwork pharmacology-based virtual screening of natural products from Clerodendrum species for identification of novel anti-cancer therapeutics.A Role for the PPARgamma in Cancer Therapy.AKR1C3 as a target in castrate resistant prostate cancerInhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor.Hypoxia triggers major metabolic changes in AML cells without altering indomethacin-induced TCA cycle deregulation.SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug-target interactions and drug repositioning.N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.Crystallization and preliminary X-ray diffraction analysis of mouse 3(17)alpha-hydroxysteroid dehydrogenase.The Recognition of Identical Ligands by Unrelated Proteins.Human cytosolic hydroxysteroid dehydrogenases of the aldo-ketoreductase superfamily catalyze reduction of conjugated steroids: implications for phase I and phase II steroid hormone metabolism.Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).Ion channel inhibitors block caspase activation by mechanisms other than restoring intracellular potassium concentration.Comparison of crystal structures of human type 3 3alpha-hydroxysteroid dehydrogenase reveals an "induced-fit" mechanism and a conserved basic motif involved in the binding of androgen.Long-chain fatty acids inhibit human members of the aldo-keto reductase 1C subfamily.Synthesis and preliminary assessment of the anticancer and Wnt/β-catenin inhibitory activity of small amide libraries of fenamates and profens.
P2860
Q27026044-F4565414-643A-4F49-9DF1-056F0D8AECBFQ27643293-49BD1EF9-0A4F-4B09-846B-FC4FCF8C2DAFQ27671816-6B3E6409-55E2-4FFA-AC06-BDA904210E2CQ27676555-DC425E63-D26F-467B-A8F0-5DE624463823Q27678541-E228E13E-D3FD-4876-B4C8-1BFED3AB2988Q27689445-5E8B4601-8C25-4772-889B-A6E87CF33A83Q27700118-21A88C3C-CA41-40A9-86D4-23FB1B2ADCB4Q28472176-F73BF7EC-9CA3-4CC4-9C32-CAD573C345F5Q30810294-08F7F28A-5EA6-403E-B6B7-F36660C54A82Q33563699-85C1877E-B302-4838-9578-C9F615515D4FQ33587153-2699087A-A873-423E-BCA8-786A749A675FQ34243803-E0E19A5C-D6CC-426E-BF49-438EE3CAF135Q34375275-951C1136-E596-406D-96FC-A27210CE67EAQ34618859-0C42C508-4A13-45FB-9153-73D62DCD88C2Q34669224-130A7B74-1421-4A6E-848F-A501076F33F2Q34795526-F40C2910-1C31-450B-8E8F-85E3A7613D28Q35102971-A7214434-AF2B-4980-A371-F21F48F89FA8Q35532230-98972727-B089-4903-8C68-6BC25B3CCFFEQ35596643-B8F7CC41-05EF-4DE1-8A17-893DCEA2DD67Q35816836-A6034480-98F5-4A76-9E3A-DF606926DDD4Q35893754-12559416-0212-4A2E-98A7-C49B1A94EAEFQ36142192-5A4E6C35-6802-491E-AC9D-0708E04004BCQ36245161-B118D696-1AD9-4B1E-9800-F06521DC1AB8Q36691611-B21B2BC2-AF2C-464B-973C-DC45A85B1087Q37248854-748FD60A-8515-40E2-A1BA-5E2B7CD34723Q38735379-66B8297E-2AA0-45F5-A77A-D0681DBBA9E6Q38754094-1FEF50C6-6646-43B7-91BB-3B8C7C0D62B4Q39649162-2A6F1692-D352-4BF5-BBCF-9D07231E09D6Q39947451-FE147E43-B3D8-4808-B4D3-1F2AEA37E15DQ40060405-6F8FCA30-C071-431E-B45E-5BC646689897Q42001834-C4B24887-D15E-4798-BCB8-5DB46E049C86Q42042812-279FDFFE-E0BD-4EA8-BD95-A39CF7F8E271Q42090716-4BE4E83B-C724-4940-8B83-0BB45508AD9BQ42689476-E401E701-501D-4399-BDFF-78B6C457F29BQ42717263-46C0A05C-9A3B-41C5-8BBF-A0CBF327C305Q43057981-580268F3-9C68-406D-9537-28E2EE4652B6Q47587182-37D91DA8-0884-4E0D-8FB2-4C18D2BBD09EQ48364155-63D14DB9-4D8E-43E4-835E-3602AA88401C
P2860
Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Crystal structures of prostagl ...... fenamic acid and indomethacin.
@ast
Crystal structures of prostagl ...... fenamic acid and indomethacin.
@en
type
label
Crystal structures of prostagl ...... fenamic acid and indomethacin.
@ast
Crystal structures of prostagl ...... fenamic acid and indomethacin.
@en
prefLabel
Crystal structures of prostagl ...... fenamic acid and indomethacin.
@ast
Crystal structures of prostagl ...... fenamic acid and indomethacin.
@en
P2093
P50
P1433
P1476
Crystal structures of prostagl ...... ufenamic acid and indomethacin
@en
P2093
Jon P Ride
Julian C Desmond
Stephen M Cummings
P304
P356
10.1158/0008-5472.CAN-03-2847
P407
P577
2004-03-01T00:00:00Z